Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198853 | 0.81 | SLC6A5 (0.49) | SLC6A5TSHRCA1CA2FAAH | |
| SCHEMBL20873757 | 0.81 | CYP1A2 (0.45) | SLC6A5EPHX2TSHRSELPCA1 | |
| SCHEMBL11142780 | 0.79 | CA1 (0.47) | SLC6A5TSHRKDM4AHIF1ATET2 | |
| SCHEMBL20710352 | 0.79 | SLC6A5 (0.51) | SLC6A5TSHRFAAHCASP2LMNA | |
| SCHEMBL10057792 | 0.79 | SLC6A5 (0.51) | SLC6A5TSHRFAAHCASP2LMNA | |
| SCHEMBL38654455 | 0.76 | ALDH1A1 (0.42) | SLC6A5TSHRKDM4AHIF1ATET2 | |
| SCHEMBL27398896 | 0.76 | PAOX (0.56) | SLC6A5TSHRKDM4AHIF1ATET2 | |
| SCHEMBL22289072 | 0.75 | SLC6A5 (0.57) | SLC6A5KDM4AHIF1ATET2DOHH | |
| SCHEMBL16421586 | 0.75 | SLC6A5 (0.57) | SLC6A5KDM4AHIF1ATET2DOHH | |
| SCHEMBL5892041 | 0.75 | TSHR (0.45) | SLC6A5TSHRCA1CA2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260038-B1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | US HEALTH (US) | 2014-12-03 | — | — | EP | claimed |
| US-8735407-B2 | Purine derivatives as A3 adenosine receptor-selective agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-27 | — | — | US | claimed |
| US-20110046166-A1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | Office of Technology Transfer, NIH (US) | 2011-02-24 | — | — | US | claimed |
| EP-2260038-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2009123881-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-10-08 | — | — | WO | claimed |
| US-8916570-B2 | A3 adenosine receptor agonists and antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2260038-B1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | US HEALTH (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8735407-B2 | Purine derivatives as A3 adenosine receptor-selective agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110046166-A1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | Office of Technology Transfer, NIH (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2260038-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009123881-A1 | PURINE DERIVATIVES AS A3 RECEPTOR- SELECTIVE AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046166-A1 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS | ADORA3, ADORA1, ADORA2A | SLC6A5 3791/4885EPHX2 1165/4885TSHR 266/4885 |
| US-20120184569-A1 | A3 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | ADORA3, ADORA1, ADORA2A | SLC6A5 3651/4885EPHX2 1376/4885TSHR 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.